The BIOSECURE Act, recently passed by the US House of Representatives, seeks to decouple the US from China’s biotech ecosystem by restricting federal funding to US firms that collaborate with major Chinese biotech players like WuXi AppTec and BGI Genomics. This legislative push reflects growing concerns over national security, intellectual property (IP) protection, and supply Continue reading »